The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.

In an Amicus Brief submitted today in Outsourcing Facilities Association v. FDA in the U.S. District Court for the Northern District of Texas, Ivim Health raises urgent concerns over the FDA's ...

Find out how an extravasation risk rating system introduced for all IV medicines has led to increased patient safety across ...